Neuromuscular Disorders News Archive

Interferon-Beta, Glatiramer Acetate Equally Effective for Relapsing-Remitting MS

Interferon-Beta, Glatiramer Acetate Equally Effective for Relapsing-Remitting MS

Investigators conducted a meta-analyses to determine whether injectable IFN-β and glatiramer acetate both decrease the annualized relapse rate and slow disease progression in patients with RRMS.

Palliative Care in MS Inpatients Rises From 2005 to 2014

Palliative Care in MS Inpatients Rises From 2005 to 2014

From 2005 to 2014, trends in palliative care use increased substantially among multiple sclerosis inpatients.

Prevalence of Pediatric Multiple Sclerosis Exceptionally High in Ontario, Canada Compared With Global Numbers

Prevalence of Pediatric Multiple Sclerosis Exceptionally High in Ontario, Canada Compared With Global Numbers

Researchers provide a practical, valid method to estimate the incidence and prevalence of MS in the pediatric population.

Certain Sites of Brain Lesions in MS Tied to Bowel Incontinence

Certain Sites of Brain Lesions in MS Tied to Bowel Incontinence

Specific locations of cerebral multiple sclerosis lesions appear to be associated with bowel incontinence.

NDA for Novel Relapsing Multiple Sclerosis Oral Treatment Submitted

NDA for Novel Relapsing Multiple Sclerosis Oral Treatment Submitted

Alkermes has submitted a New Drug Application to the FDA for a novel oral fumarate in development to treat relapsing forms of multiple sclerosis.

Family Planning in MS: Dispelling Myths and Encouraging Conversations

Family Planning in MS: Dispelling Myths and Encouraging Conversations

Rosalind C. Kalb, PhD, a clinical psychologist, offers her insights on how clinicians can address patient concerns about reproductive issues and MS.

Side Effects, Tolerability of Newer DMTs Similar in Pediatric, Adult Multiple Sclerosis

Side Effects, Tolerability of Newer DMTs Similar in Pediatric, Adult Multiple Sclerosis

Children with MS were more likely to receive a newer DMT prior to turning 18 years old compared with patients with CIS.

FDA Warns of Rare Stroke Risk With Multiple Sclerosis Drug

FDA Warns of Rare Stroke Risk With Multiple Sclerosis Drug

A new warning has been added to the multiple sclerosis drug Lemtrada (alemtuzumab) after rare reports of patients suffering strokes and tears in the lining of the arteries in the head and neck.

MS Relapse Drops During Pregnancy but Rises After

MS Relapse Drops During Pregnancy but Rises After

Rates of multiple sclerosis relapse decrease during pregnancy but increase postpartum.

Many Patients Do Not Engage Health Care Provider During MS Relapse

Many Patients Do Not Engage Health Care Provider During MS Relapse

The rate and frequency of relapse vary for patients with multiple sclerosis, and many report not visiting a health care provider during relapse.

FDA: Risk of Severe Increase in Disability Following MS Treatment Discontinuation

FDA: Risk of Severe Increase in Disability Following MS Treatment Discontinuation

From September 2010 to February 2018, the FDA has identified 35 cases of severe increased disability accompanied by the presence of new lesions on MRI that occurred 2 to 24 weeks after stopping treatment with fingolimod.

Ocrevus Labeling Updated With New Info on Timing of Vaccine Administration

Ocrevus Labeling Updated With New Info on Timing of Vaccine Administration

According to a Phase 3b open-label study, Ocrevus may interfere with the effectiveness of non-live vaccines.

Approaches for Better Diagnosis of Pediatric Multiple Sclerosis

Approaches for Better Diagnosis of Pediatric Multiple Sclerosis

Pediatric MS is predominantly inflammatory in nature, with a presentation that is similar to a number of other conditions.

Incidence of Guillain-Barré Syndrome Linked With Recent Bone, Digestive Organ Surgery

Incidence of Guillain-Barré Syndrome Linked With Recent Bone, Digestive Organ Surgery

A nationwide epidemiologic study in France examined a correlation between Guillain-Barré syndrome and recent bone or digestive organ surgery.

Nusinersen May Be Effective for Short-Term Motor Function Improvements in Spinal Muscular Atrophy

Nusinersen May Be Effective for Short-Term Motor Function Improvements in Spinal Muscular Atrophy

Nusinersen, an antisense oligonucleotide that increases functional SMN protein production from SMN2, was clinically effective for improving motor function.

Comorbidities in Multiple Sclerosis: Effects on DMTs, the Treatment Team, and More

Comorbidities in Multiple Sclerosis: Effects on DMTs, the Treatment Team, and More

Having a higher burden of comorbidities is associated with greater disability progression and lower QoL, as well as increased healthcare utilization and mortality.

Rates of Multiple Sclerosis Relapses Vary Before, During, and After Pregnancy

Rates of Multiple Sclerosis Relapses Vary Before, During, and After Pregnancy

Investigators sought to determine relapse rates of multiple sclerosis decrease prior to pregnancy, during pregnancy, and postpartum.

Tiglutik Now Available for the Treatment of Amyotrophic Lateral Sclerosis

Tiglutik Now Available for the Treatment of Amyotrophic Lateral Sclerosis

Tiglutik is supplied as a thickened riluzole liquid that is intended to ease administration for patients with dysphagia.

A New Look at Demyelination and White Matter Density in Multiple Sclerosis

A New Look at Demyelination and White Matter Density in Multiple Sclerosis

Investigators propose that myelocortical multiple sclerosis may be a subtype of multiple sclerosis.

Cannabinoids Mildly Effective for Treating MS Symptoms in Adults

Cannabinoids Mildly Effective for Treating MS Symptoms in Adults

Cannabinoids may be mildly effective at treating spasticity, pain, and bladder dysfunction in adults with multiple sclerosis.

Fingolimod shows superior efficacy to interferon beta-1a in pediatric multiple sclerosis: the PARADIGMS trial

Among pediatric patients with relapsing multiple sclerosis, fingolimod was associated with a lower annualized rate of relapse and lower incidence of new lesions identified on T2-weighted magnetic resonance imaging (MRI) compared to interferon beta-1a.

Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis

Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis

Investigators examine the role of physical activity and exercise in the modification of vascular comorbidities and risk factors in individuals with multiple sclerosis.

DMTs Do Not Moderate Disability in Patients With MS and Diabetes, Other Comorbidities

DMTs Do Not Moderate Disability in Patients With MS and Diabetes, Other Comorbidities

All participants were smokers or had either diabetes, cancer, depression, cardiovascular, respiratory, thyroid, or gastrointestinal disease and were receiving a DMT.

Glatiramer Acetate Associated With Long-Term Disability Improvements in MS

Glatiramer Acetate Associated With Long-Term Disability Improvements in MS

Natural history data from a subset of patients from the British Columbia MS database between 1980 to 1996 were used to create a continuous Markov model to model the projected course of disease in untreated people with RMS.

Fingolimod Compared With Glatiramer Acetate in Head-to-Head MS Study

Fingolimod Compared With Glatiramer Acetate in Head-to-Head MS Study

Compared with Copaxone injection, treatment with oral Gilenya significantly reduced the annualized relapse rate in patients with relapsing remitting multiple sclerosis.

Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis

Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis

Researchers categorized samples into quintiles based on 25(OH)D3 concentrations in healthy controls.

High-Dose Biotin May Be an Effective Treatment for Progressive MS

High-Dose Biotin May Be an Effective Treatment for Progressive MS

Patients with progressive MS or secondary progressive MS who were receiving care at a single institution in France were prescribed 300 mg/day MD1003.

Lower Relapse Risk and Disability Progression With Oral DMT in Treatment-Naive RRMS

Lower Relapse Risk and Disability Progression With Oral DMT in Treatment-Naive RRMS

In patients with relapse-remitting multiple sclerosis, the initiation of oral disease-modifying therapies is associated with a lower relapse risk as well as a lower risk for disability progression.

MS Relapse Rates After DMT Initiation Similar Between Pediatric-, Adult-Onset MS

MS Relapse Rates After DMT Initiation Similar Between Pediatric-, Adult-Onset MS

Disability progression is slower among patients with pediatric-onset multiple sclerosis.

Patients With Multiple Sclerosis Face Greater Infection Risk

Patients With Multiple Sclerosis Face Greater Infection Risk

Patients with MS also have a higher risk for serious hospitalized-related infections compared with hospitalized patients without MS.

Disease Modifying Therapy Associated With Persistent Brain Atrophy Slowing in MS

Disease Modifying Therapy Associated With Persistent Brain Atrophy Slowing in MS

Investigators examine the effect of disease-modifying therapy on the rate of brain atrophy in patients with multiple sclerosis.

Alemtuzumab Improves Disability, Prognosis in Treatment-Refractory MS

Alemtuzumab Improves Disability, Prognosis in Treatment-Refractory MS

Study investigators assessed the changes in the Expanded Disability Status Scale and MS Severity Score after up to 7 courses of alemtuzumab.

Fingolimod Significantly Improves Quality of Life in Pediatric MS

Fingolimod Significantly Improves Quality of Life in Pediatric MS

The phase 3 PARADIGMS trial involving 215 pediatric patients demonstrated superior efficacy for fingolimod over interferon beta-1a.

Use of Disease Modifying Therapies for Multiple Sclerosis Has No Ill Effect on Pregnancy Outcomes

Use of Disease Modifying Therapies for Multiple Sclerosis Has No Ill Effect on Pregnancy Outcomes

Patients were divided into 3 groups: patients not treated in the 3 months before pregnancy, patients treated in the 3 months before pregnancy, and patients treated during pregnancy.

Serious Adverse Events Profile for Cladribine Confirmed With Extended Data

Serious Adverse Events Profile for Cladribine Confirmed With Extended Data

Researchers pooled long-term data on the safety of cladribine tablets monotherapy that extended 3 or more years beyond the data included in the last clinical study.

Copaxone 3 Times Weekly Safe, Effective for Ambulatory Patients With Relapsing MS

Copaxone 3 Times Weekly Safe, Effective for Ambulatory Patients With Relapsing MS

Participants showed a significant decrease in annual relapse rate and a significant improvement in both patient-reported disability scores and information processing scores.

Ozanimod Reduces Severe Relapses in Multiple Sclerosis More Than Interferon Beta-1a

Ozanimod Reduces Severe Relapses in Multiple Sclerosis More Than Interferon Beta-1a

Treatments were evaluated for either 1 year (SUNBEAM) or 2 years (RADIANCE).

Multiple Sclerosis Comorbidities Affect Work Participation, Daily Function

Multiple Sclerosis Comorbidities Affect Work Participation, Daily Function

Surveys were given out to individuals in the Australian Multiple Sclerosis Longitudinal Study between August and December 2016.

Use of Walking Aids May Predict Participation Levels in Patients With MS

Use of Walking Aids May Predict Participation Levels in Patients With MS

Investigators examined factors associated with mobility and walking restrictions in participants with multiple sclerosis.

Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis

Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis

Researchers analyze the dietary habits of 260 patients in the early stages of multiple sclerosis from baseline to 5 years after initial onset of symptoms.

Long-Term Ocrelizumab Reduces Relapse Rate and Disability Progression in MS

Long-Term Ocrelizumab Reduces Relapse Rate and Disability Progression in MS

Patients with multiple sclerosis who initiated ocrelizumab therapy earlier and continued long-term treatment sustained lower annualized relapse rates.

Cladribine Tablets Reduce Relapses in Relapsing-Remitting Multiple Sclerosis

Cladribine Tablets Reduce Relapses in Relapsing-Remitting Multiple Sclerosis

Reserachers evaluated data from the CLARITY study to test the efficacy of cladribine tablets on frequency and severity of relapses for patients with multiple sclerosis.

Risk for Acute Myocardial Infarction Increased in Multiple Sclerosis

Risk for Acute Myocardial Infarction Increased in Multiple Sclerosis

Evidence suggests a possible role for inflammation in the association between MS and myocardial infarction risk.

Extended Interval Dosing of Natalizumab Does Not Reduce Efficacy in MS

Extended Interval Dosing of Natalizumab Does Not Reduce Efficacy in MS

Extended interval dosing of natalizumab may also be associated with reduced risk for progressive multifocal leukoencephalopathy.

Dimethyl Fumarate Therapy Reduces Relapse Rates in Early Multiple Sclerosis

Dimethyl Fumarate Therapy Reduces Relapse Rates in Early Multiple Sclerosis

The ESTEEM study included 3075 patients who were newly prescribed dimethyl fumarate to manage relapsing-remitting multiple sclerosis.

Early Disease Modifying Therapy Initiation Associated With Improved MS Relapse Control

Early Disease Modifying Therapy Initiation Associated With Improved MS Relapse Control

Early initiation of dimethyl fumarate and fingolimod may be associated with improved relapse control in multiple sclerosis relative to late therapy initiation.

Patients With MS Who Use Tobacco at Greater Risk for Disease Activity

Patients With MS Who Use Tobacco at Greater Risk for Disease Activity

Multiple sclerosis disease activity was less likely to decrease among tobacco users.

Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis

Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis

Previous studies have shown that excess adiposity is a strong risk factor for metabolic comorbidities and has been linked to poorer outcomes in people with neurologic diseases.

Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis

Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis

Higher depressive symptoms in patients with multiple sclerosis was associated with lower employment and processing speed.

FDA Issues Safety Communication Regarding Pen Needle Use

FDA Issues Safety Communication Regarding Pen Needle Use

Standard pen needles have an outer cover and removable inner needle cover, while safety pen needles have an outer cover and a fixed inner needle shield that is not removed before an injection.

Exploring the Benefits of Virtual Reality Rehabilitation in Multiple Sclerosis

Exploring the Benefits of Virtual Reality Rehabilitation in Multiple Sclerosis

Future studies on VR training for MS should include large randomized controlled trials using clear protocols and comparable between-group tasks.

Lower Levels of Depression, Higher QOL for Older MS Patients

Lower Levels of Depression, Higher QOL for Older MS Patients

Older individuals with multiple sclerosis report less severe depressive symptoms and better physical quality of life, compared to younger patients.

Alpha and Beta Band Activity in MS-Related Chronic Pain

Alpha and Beta Band Activity in MS-Related Chronic Pain

Patients with multiple sclerosis-related chronic pain were found to have spectral abnormalities within the dynamic pain connectome regions.

Psychiatric Adverse Effects of Disease-Modifying Therapies Assessed in Multiple Sclerosis

Psychiatric Adverse Effects of Disease-Modifying Therapies Assessed in Multiple Sclerosis

The primary outcome measure of the study was the frequency of any adverse psychiatric effect observed during treatment with one of these agents.

Serum-Leptin and Adiponectin Not Suitable Biomarkers for Multiple Sclerosis

Serum-Leptin and Adiponectin Not Suitable Biomarkers for Multiple Sclerosis

Investigators examined whether serum leptin and adiponectin could be potential biomarkers of disease activity in multiple sclerosis.

Brain Iron on MRI Linked to Disability in Multiple Sclerosis

Brain Iron on MRI Linked to Disability in Multiple Sclerosis

Brain iron at quantitative magnetic resonance imaging is associated with disability in multiple sclerosis.

AANEM 2018: Key Programming on Neuromuscular and Electrodiagnostic Medicine

AANEM 2018: Key Programming on Neuromuscular and Electrodiagnostic Medicine

The 2018 AANEM Annual Meeting is taking place at the Gaylord National Resort & Convention Center in Washington, DC.

Fingolimod Cuts Multiple Sclerosis Relapses in Pediatric Patients

Fingolimod Cuts Multiple Sclerosis Relapses in Pediatric Patients

Among pediatric patients with relapsing multiple sclerosis, fingolimod is associated with a lower rate of relapse but a higher rate of serious adverse events.

Ibudilast Appears to Slow Brain Atrophy Progression in MS

Ibudilast Appears to Slow Brain Atrophy Progression in MS

In patients with progressive multiple sclerosis, slower progression of brain atrophy was seen with ibudilast versus placebo.

Gene Variant Linked to Liver Injury Risk in Interferon-Treated MS

Gene Variant Linked to Liver Injury Risk in Interferon-Treated MS

Following adjustment for MS disease course, the genome-wide analysis identified an association between chromosome 1q32.2 and IFN-β-induced liver injury.

Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment

Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment

Although regarded as a miracle drug to some, nusinersen comes with some troublesome strings attached.

DMD Treatment Gets Orphan Drug, Rare Pediatric Disease Designations

DMD Treatment Gets Orphan Drug, Rare Pediatric Disease Designations

DMD is predominately caused by out-of-frame deletions in the dystrophin gene, which results in absent or defective dystrophin protein, leading to progressive and irreversible muscle function loss.

Presence of CHI3L1 and NFL in CSF Predicts Risk for Demyelinating Syndromes

Presence of CHI3L1 and NFL in CSF Predicts Risk for Demyelinating Syndromes

Investigators assess the diagnostic value of 2 CSF biomarkers to distinguish pediatric acquired demyelinating syndromes from non-acquired demyelinating syndromes.

OCD in Duchenne Muscular Dystrophy Features Distinct Phenotype, Associated Symptoms

OCD in Duchenne Muscular Dystrophy Features Distinct Phenotype, Associated Symptoms

Investigators aim to facilitate early recognition and consideration for patients with Duchenne muscular dystrophy and internalizing psychiatric symptoms.

FDA Accepts NDA Resubmission for Oral Cladribine in Relapsing MS

FDA Accepts NDA Resubmission for Oral Cladribine in Relapsing MS

The NDA resubmission is in response to the FDA's Complete Response Letter issued in 2011 which requested an improved understanding of the safety risks and overall benefit-risk profile.

Organic Solvents Plus Genetics May Increase Risk of Multiple Sclerosis

Organic Solvents Plus Genetics May Increase Risk of Multiple Sclerosis

The combination of genetics and exposure to organic solvents in paints and varnishes increases the risk of multiple sclerosis.

Dynamics of Brain Volume Loss Vary With MS Progression

Dynamics of Brain Volume Loss Vary With MS Progression

Brain volume loss has nonlinear dynamics and limited reproducibility as a marker of therapeutic response in multiple sclerosis.

Understanding ICU-Acquired Neuromuscular Dysfunction: Triggers, Risk Factors, and Treatments

Understanding ICU-Acquired Neuromuscular Dysfunction: Triggers, Risk Factors, and Treatments

ICU-acquired weakness syndromes manifest themselves in a range of ways among patients — as a spectrum of disease rather than in specific form.

FDA Lifts Clinical Hold on Trial for Duchenne Muscular Dystrophy Treatment

FDA Lifts Clinical Hold on Trial for Duchenne Muscular Dystrophy Treatment

SGT-001 is a novel adeno-associated viral vector mediated gene transfer that could potentially address the underlying genetic cause of DMD, mutations in the dystrophin gene.

Reduced Disability Progression, Adverse Events Top Considerations When Selecting MS Therapy

Reduced Disability Progression, Adverse Events Top Considerations When Selecting MS Therapy

A majority of the respondents in both groups identified reduced disability progression as a priority.

Immunotherapy Promising for Slowing Progression of ALS

Immunotherapy Promising for Slowing Progression of ALS

A new immunotherapy appears to be well tolerated and possibly of benefit in patients with amyotrophic lateral sclerosis.

Gait in Multiple Sclerosis Improved With Dalfampridine Plus Physical Therapy

Gait in Multiple Sclerosis Improved With Dalfampridine Plus Physical Therapy

A combination of dalfampridine extended-release and physical therapy (PT) has shown efficacy for improving gait in people with multiple sclerosis

Medical Cannabis Shows Promise in Treating Symptoms of Multiple Sclerosis

Medical Cannabis Shows Promise in Treating Symptoms of Multiple Sclerosis

Differing formulations and ratios of the subjects' medical cannabis regimens have been accounted for, though further information about ratios of CBD and TCH are subject to change due to continued ongoing research.

Multiple Sclerosis Pain Common Disruptive Factor in Everyday Activities

Multiple Sclerosis Pain Common Disruptive Factor in Everyday Activities

Pain in patients with multiple sclerosis may affect their daily functioning regardless of disease severity.

Dimethyl Fumarate Not Associated With Greater Pain vs Other DMTs in Relapsing-Remitting MS

Dimethyl Fumarate Not Associated With Greater Pain vs Other DMTs in Relapsing-Remitting MS

Investigators assessed the effect of disease-modifying treatments on pain in patients with relapsing-remitting multiple sclerosis.

Skin Tone, Race May Be Associated With Multiple Sclerosis Diagnosis

Skin Tone, Race May Be Associated With Multiple Sclerosis Diagnosis

The MS and monophasic ADS groups were compared using quantified melanin measurements via the DSM II Colorimeter; self-reported skin tones of fair, medium, olive, or dark; a self-reported race; and skin tone, which was self-reported using 10 numerical panels of color.

Proposed Protocol Taps Occupational Therapist for Assistance With MS Medication Adherence

Proposed Protocol Taps Occupational Therapist for Assistance With MS Medication Adherence

The protocol authors propose a more objective method of managing medication adherence through a profile performed by an occupational therapist.

Optimized Urinalysis Reflex Reduces Urine Culture Orders in MS

Optimized Urinalysis Reflex Reduces Urine Culture Orders in MS

Due to the increased risk for urinary tract infections (UTIs) in people with MS and similar CNS demyelinating diseases, as well as the tendency of UTIs to trigger more MS flares, the affected population are subject to a large number of unneeded antibiotic prescriptions and asymptomatic bacteriuria treatments.

Certain Comorbidities More Common in People With Multiple Sclerosis

Certain Comorbidities More Common in People With Multiple Sclerosis

The study researchers examined data from the US database of the IMS Health Real World Data Adjudicated Claims between 2011 and 2015.

Tuberculosis Common in MS Treated With Immunosuppressive Agents

Tuberculosis Common in MS Treated With Immunosuppressive Agents

Immunotherapy in multiple sclerosis may increase the risk for conversion from latent to active tuberculosis infection.

Ozanimod Superior to Interferon for Relapsing Multiple Sclerosis

Ozanimod Superior to Interferon for Relapsing Multiple Sclerosis

This study analyzed results from SUNBEAM (ClinicalTrials.gov Identifier: NCT02294058) and RADIANCE (ClinicalTrials.gov Identifier: NCT01628393), 2 double-blind, randomized, phase 3 trials.

Ocrelizumab May Improve Cognition in Patients At Risk for Progressive Multiple Sclerosis

Ocrelizumab May Improve Cognition in Patients At Risk for Progressive Multiple Sclerosis

Cognitive impairment is common in patients with multiple sclerosis (MS) and considerably impacts quality of life.

Alemtuzumab Reduces MRI Disease Activity, Brain Volume Loss in Relapsing-Remitting MS

Alemtuzumab Reduces MRI Disease Activity, Brain Volume Loss in Relapsing-Remitting MS

Alemtuzumab is associated with reduced magnetic resonance imaging disease activity and the slowing of brain volume loss over 7 years in patients with relapsing-remitting multiple sclerosis.

Fingolimod Improves Multiple Sclerosis Outcomes After Previous DMT Failure

Fingolimod Improves Multiple Sclerosis Outcomes After Previous DMT Failure

Brain volume loss was smaller for all groups after treatment with fingolimod.

Ublituximab Associated With Significant Reduction in MS Disease Activity, Focal Lesions

Ublituximab Associated With Significant Reduction in MS Disease Activity, Focal Lesions

TG1101-RMS201 was a multicenter, placebo-controlled, phase 2, 52-week study designed to evaluate the optimal infusion and safety of ublituximab for relapsing multiple sclerosis.

Long-Term Teriflunomide for MS Not Associated With Grade 3 Lymphopenia

Long-Term Teriflunomide for MS Not Associated With Grade 3 Lymphopenia

Analysis of yearly lymphocyte counts showed a declining occurrence of all grades of lymphopenia over time, and by year 9, subjects exhibited no cases of lymphopenia.

MS Relapse, EDSS Score Predict Long-Term Clinical Outcomes

MS Relapse, EDSS Score Predict Long-Term Clinical Outcomes

The multiple-logistic regression analyses determined that the most consistent predictors for negative clinical outcomes in months 12 to 48 were relapses during months 0 to 12 and EDSS scores at baseline and months 0 to 12.

Risk for Multiple Sclerosis Relapse Low in Transition From Natalizumab to Dimethyl Fumarate

Risk for Multiple Sclerosis Relapse Low in Transition From Natalizumab to Dimethyl Fumarate

This retrospective cohort study sought to assess the outcomes for individuals with multiple sclerosis who transitioned from natalizumab to dimethyl fumarate.

Ocrelizumab Decreases Humoral Response to 4 Vaccines in Multiple Sclerosis

Ocrelizumab Decreases Humoral Response to 4 Vaccines in Multiple Sclerosis

The VELOCE trial (ClinicalTrials.gov Identifier: NCT02545868) was an open-label, randomized, phase 3b study designed to assess whether ocrelizumab could raise the humoral responses to vaccines in individuals with relapsing multiple sclerosis.

Long-Term Efficacy of Alemtuzumab Sustained Without Continuous Treatment in RRMS

Long-Term Efficacy of Alemtuzumab Sustained Without Continuous Treatment in RRMS

Investigators explored the efficacy and safety of alemtuzumab in patients initially assigned to alemtuzumab in a previous trial followed by alemtuzumab treatment over a 2-year period in a core study plus an additional 4-year period in an extension trial.

Association Between Vitamin D Supplementation, Multiple Sclerosis Relapse Still Unclear

Association Between Vitamin D Supplementation, Multiple Sclerosis Relapse Still Unclear

Although the study demonstrated a lower relapse rate among patients with MS who supplemented their diet with vitamin D, the analysis did not reach statistical significance.

Twice-Weekly Interferon Beta-1a Effective for Reducing MS Relapse

Twice-Weekly Interferon Beta-1a Effective for Reducing MS Relapse

A prospective, blinded, randomized trial comparing once-weekly and twice-weekly IM IFNβ-1a may be indicated.

Depression, Fatigue Predict Adherence to Multiple Sclerosis Therapies

Depression, Fatigue Predict Adherence to Multiple Sclerosis Therapies

Patients with higher rates of depression and fatigue were significantly more likely to have lower MMAS-8 adherence scores.

Obesity Associated With Greater Relapse Activity, Impaired Function in MS

Obesity Associated With Greater Relapse Activity, Impaired Function in MS

The investigators examined the association between obesity and the age of first symptom(s), number of impaired functional domains, and early relapse activity in patients with MS.

Various Clinical Disturbances Precede MS Diagnosis

Various Clinical Disturbances Precede MS Diagnosis

Various clinical symptoms precede the diagnosis of multiple sclerosis by several years.

Eculizumab May Improve Independent Walking Ability in Guillain-Barré Syndrome

Eculizumab May Improve Independent Walking Ability in Guillain-Barré Syndrome

High-dose intravenous immunoglobulin therapy was administered to all patients and may have contributed to neutralization of eculizumab.

FDA Approves First Multiple Sclerosis Treatment for Pediatric Patients

FDA Approves First Multiple Sclerosis Treatment for Pediatric Patients

The FDA's decision was based on data from the Phase 3 PARADIGMS study (N=215) which evaluated the safety and efficacy of oral fingolimod vs interferon beta-1a injection in pediatric patients aged 10 to <18 years with relapsing MS.

Facioscapulohumeral Muscular Dystrophy Treatment Gets Fast Track Status

Facioscapulohumeral Muscular Dystrophy Treatment Gets Fast Track Status

ACE-083 is currently being studied in a Phase 2 trial for FSHD and another for Charcot-Marie-Tooth (CMT) disease.

Online Fatigue Management Feasible, Effective for Multiple Sclerosis

Online Fatigue Management Feasible, Effective for Multiple Sclerosis

Investigators designed a parallel-group, 2-arm, randomized controlled trial to evaluate ELEVIDA, an online fatigue management program based on cognitive behavioral therapy and other therapy-based strategies.

Dimethyl Fumarate May Be Safe, Effective for Pediatric Multiple Sclerosis

Dimethyl Fumarate May Be Safe, Effective for Pediatric Multiple Sclerosis

Previous studies have shown that delayed-release DMF is safe and effective in treating RRMS in adult patients. The goal of this study was to extend these analyses to evaluate DMF in pediatric patients with RRMS.

Sign Up for Free e-newsletters



CME Focus